Other
NING LI
Total Trials
2
Recruiting
0
Active
1
Completed
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
Failure Rate
0.0%
0 terminated/withdrawn out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Early Phase 1
1(50.0%)
Phase 4
1(50.0%)
2Total
Early Phase 1(1)
Phase 4(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (2)
Showing 2 of 2 trials
NCT06610227Early Phase 1Active Not Recruiting
A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors
Role: lead
NCT06824792Phase 4Not Yet Recruiting
Optimal Standard Treatment Selection for Solid Tumor Patients by Biologically-informed Multi-agent System
Role: lead
All 2 trials loaded